7 Interdisciplinary Companies Close New Funding Rounds | FreeS Family Funding News Vol.22

The "FreeS Family Funding News" column periodically shares updates on portfolio companies' fundraising rounds. Coverage includes both new investments and follow-on rounds for existing portfolio companies. We witness each step as innovative ventures grow from 0 to 1, 1 to 10, and 10 to 100.

This edition at a glance:

• Tech + Healthcare: FreeS Fund angel-round portfolio company Qingpai Technology closed a tens-of-millions RMB Pre-A round, with FreeS reinvesting; FreeS Fund angel-round portfolio company Qiongdin Medical closed a tens-of-millions RMB Series A.
• Consumer + Healthcare: FreeS Fund Series A portfolio company Methuselah closed a nearly 200 million RMB Series B, with FreeS reinvesting.
• Embodied Intelligence: FreeS Fund angel-round portfolio company LimX Dynamics closed an A+ round, bringing its total A-round series to 500 million RMB over six months, with FreeS reinvesting.
• Bio-manufacturing: FreeS Fund angel-round portfolio company Yanwei Technology closed a new funding round.
• Advanced Manufacturing: FreeS Fund angel-round portfolio company UJet Future closed a tens-of-millions RMB A+ round, with FreeS reinvesting; FreeS Fund angel-round portfolio company Chuguang 3D closed a tens-of-millions RMB angel+ round, with FreeS reinvesting.

(Funding information in this roundup covers public disclosures from February to March 2025, ordered by announcement date.)

▲ Image source: Qingpai Technology

FreeS Fund angel-round portfolio company Qingpai Technology announced the completion of a tens-of-millions RMB Pre-A funding round. Participants in this round include GTJA Investment, Chengmei Capital, and Xiamen High-tech Investment, with existing shareholder FreeS Fund reinvesting.

/ From the Investors /

Biomedical imaging equipment has consistently evolved toward higher dimensions — from 2D to 3D, from structural to functional imaging, from single-spectrum to hyperspectral. Photoacoustic imaging combines the strengths of optical and ultrasound imaging, offering high-precision 3D imaging, functional imaging, molecular imaging, and non-invasive, non-destructive capabilities. It provides a new perspective for in vivo imaging and richer biological tissue information for clinicians, aligning with the major trends in precision medicine and biomedical imaging development.

Starting from first principles, Qingpai Technology centers on algorithmic innovation, possesses core hardware R&D capabilities, and maintains close clinical partnerships. We've observed that Qingpai's commercialization strategy is clear and methodical — the team is excellent and pragmatic. We look forward to Qingpai leading the development of the photoacoustic imaging field.

/ About the Company /

Qingpai Technology is a specialized photoacoustic imaging team focused on the innovative R&D, sales, and clinical and research application of photoacoustic imaging systems and core components.

The team provides scientists and clinical experts with quality photoacoustic bio-imaging products and technical services, supporting cutting-edge research in life sciences, pharmacology, and medicine.

The company currently offers the Marsonics PIIP photoacoustic integrated imaging platform (2D tomographic imaging with tomosynthesis-based 3D reconstruction), the PIIP3D photoacoustic 3D imaging system (isotropic high-resolution 3D non-real-time imaging), and the CPIIP photoacoustic clinical integrated imaging trial system (primarily for clinical trials). The RT-PIIP3D real-time 3D photoacoustic imaging system is scheduled for release in 2025. (Coverage: Zhongguancun Zhiyou Research Institute — Qingpai Technology Completes Tens-of-Millions RMB Pre-A Round to Advance Clinical Photoacoustic Imaging System Commercialization)

▲ Image source: Methuselah

FreeS Fund Series A portfolio company Methuselah announced the completion of a nearly 200 million RMB Series B funding round. This round was co-led by CICC Capital, Hongsheng Capital, and HLC, with Fengqiao Capital and FreeS Fund participating.

/ From the Investors /

As Methuselah's first institutional investor, FreeS Fund has been deeply involved in the company's strategic development since its very first fundraising round, and has now completed its third follow-on investment. Methuselah has demonstrated strong foresight in strategic planning, and we firmly believe in the long-term prospects of China's medical nutrition industry.

Methuselah is one of the few domestic medical nutrition companies to achieve synergistic development across three major product lines: foods for special medical purposes (FSMP), low-GI foods, and energy-control foods. We are optimistic about Methuselah's potential for sustained growth. Leveraging FreeS Fund's accumulated industry-university-research resources in biomedicine, we will continue to support Methuselah in expanding its market presence and accelerating the high-quality development of China's medical nutrition industry.

/ About the Company /

Methuselah is a large-scale medical nutrition technology enterprise integrating R&D, production, and sales. The company has formed strategic alliances with major US medical food technology companies and partnered with multiple domestic clinical nutrition expert teams to develop a range of medical nutrition products tailored to Chinese populations, adhering to the philosophy of "different nutrition for different people."

Its two flagship series, "DGI" and "Control Energy," focus respectively on low-glycemic foods and medical nutrition weight management products, encompassing over 100 SKUs. With exceptional quality, outstanding taste, and precise market positioning, the company's products have successfully entered major retailers including Sam's Club, Costco, and Bailian, reaching mass consumers directly. (Coverage: VB Network — Medical Nutrition Leader Methuselah Completes New Round of Nearly 200 Million RMB Funding)

▲ Image source: Qiongdin Medical

FreeS Fund angel-round portfolio company Qiongdin Medical completed a tens-of-millions RMB Series A funding round. This round was co-led by Huafang Capital and iFlytek Ventures, with Heying Capital participating.

/ From the Investors /

In brain science, research into the mechanisms of human brain function and the development of neuromodulation technologies have opened possibilities for regulating brain activity and intervening in brain disorders through physical fields. Neuromodulation technology has evolved for nearly 60 years, yet technologies that simultaneously achieve non-invasive, deep-brain, and precise modulation remain scarce.

Qiongdin has developed a series of neuromodulation products using electrical stimulation, ultrasound stimulation, and magnetic stimulation based on Temporal Interference (TI) technology, providing new tools for clinical research and treatment of brain disorders. The company has achieved industry-leading clinical progress across multiple indications. FreeS Fund is optimistic about Qiongdin efficiently and solidly completing clinical validation of TI technology, providing innovative brain disorder treatment solutions from China.

/ About the Company /

The potential therapeutic demand in brain science is enormous — China has nearly 130 million patients with various brain disorders, including over 50 million with depression, and the burden of brain disorders accounts for 23% of the total disease burden.

In brain science, Qiongdin Medical has spent nearly a decade深耕 the field of non-invasive neuromodulation, continuously refining TI technology and becoming the first to master and achieve non-invasive deep-brain precise neuromodulation using TI in humans.

Qiongdin's TI products can accurately output different stimulation signal patterns, with parameters finely adjusted according to clinical needs, enabling non-invasive, deep-brain, high-precision, multi-target central nervous system stimulation intervention. These capabilities can be widely applied to the treatment of various neurological and psychiatric disorders. (Coverage: VB Network — Global TI Leader Qiongdin Medical Completes Series A, Breaking New Ground in Non-Invasive Deep-Brain Neuromodulation)

▲ Image source: LimX Dynamics

FreeS Fund angel-round portfolio company LimX Dynamics announced the completion of an A+ funding round, bringing its total A-round series to 500 million RMB over six months. The company received strategic support from leading industry and financial institutions, with multiple existing shareholders continuing to participate. Strategic industry investors include Alibaba, China Merchants Capital, Shangqi Capital, NIO Capital, Lenovo Capital and Incubator Group, Bian Age, and Nice Group. Notable financial investors include Gaojie Capital, Oasis Capital, Future Capital, FreeS Fund, and Shenzhen Nanshan Strategic Emerging Industry Investment.

/ From the Investors /

In embodied intelligence and humanoid robotics, the industry is transitioning comprehensively from the critical technology R&D phase to productization and commercialization. The hardware design and manufacturing of robot bodies, the development of embodied brain systems, and reinforcement learning-driven whole-body control technology — these three core elements synergize and iterate continuously, forming a technology flywheel that drives the industry forward and serves as the key enabler for robot productization and commercialization.

After years of deep cultivation, LimX Dynamics has successfully built a hardware product system encompassing full-size high-performance robots and the multi-form bipedal robot TRON 1, while continuously advancing its VGM (VideoGenMotion) embodied manipulation algorithms and Agent development toolchain. We believe that with solid technical accumulation and product positioning, LimX Dynamics will empower downstream industries, effectively assist humans in diverse industrial and service scenarios, launch commercially valuable Agent-level robot products, and help the industry achieve leapfrog development.

/ About the Company /

Founded in 2022, LimX Dynamics focuses on full-size general-purpose humanoid robots and derived bipedal products, built around three core embodied intelligence technologies: hardware design and manufacturing, reinforcement learning-based whole-body motion control, and embodied brain model training strategies.

With fully self-developed core software and hardware technologies combined with humanoid foundation models, LimX Dynamics provides humanoid robot body software and hardware systems and embodied Agent development toolchains to enterprise customers, system integrators, and individual developers through its general mobile manipulation platform and embodied intelligence software tools, driving broad application of embodied intelligence in research, manufacturing, commerce, and home settings.

The company has recently achieved a series of key advances in AI exploration, algorithm R&D, and hardware design and manufacturing for robotics. (Coverage: 36Kr Pro — Humanoid Robot Company Raises 500 Million RMB in Six Months, Backed by Alibaba, NIO, Lenovo)

▲ Image source: Yanwei Technology

FreeS Fund angel-round portfolio company Yanwei Technology received investment from SDIC Chuangyi, completing a new funding round.

/ From the Investors /

Congratulations to Yanwei Technology on completing this new round and gaining support from a national team investor. FreeS Fund led Yanwei's angel round and has continued to increase our support through multiple subsequent rounds. In our early investment, we were optimistic about Yanwei's two chassis cell platforms based on rhodococcus and bacillus, and its deep technical foundation.

After three years of development, Yanwei has lived up to expectations, developing lipid-based biostimulants and derived molecules, and creating multiple rhodococcus catalysts. The company has also achieved 10,000-ton production capacity, proactively built out R&D platforms, expanded its talent team, and ultimately achieved substantial commercial monetization. Congratulations again — we look forward to Yanwei becoming a leader in China's bio-manufacturing sector.

/ About the Company /

Founded in 2022, Yanwei Technology focuses on bio-manufacturing and application development of whole-cell catalysts and bio-based surfactants, with rhodococcus and bacillus as its two core chassis cells. Downstream applications cover oilfield chemicals, agricultural food, and daily-use cosmetics and medical aesthetics.

Yanwei's developed bacillus lipid-based biostimulant is the first commercially available product of its kind globally. It significantly promotes fertilizer absorption, regulates plant metabolism and physiological states, improves soil microbiome structure and fertility, and enhances crop stress resistance. It has achieved significant yield and quality improvements across over 70 crop types in 25 regions nationwide, with advantages including low effective concentration, broad applicability, high cost-effectiveness, and convenient application. (Coverage: Synthetic Biology Network — SDIC Enters Synthetic Biology Again, Yanwei Technology Secures New Funding! Synthetic Biology Product Achieves Global First Commercialization!)

▲ Image source: UJet Future

FreeS Fund angel-round portfolio company UJet Future announced the consecutive completion of Series A and A+ equity financing, with total proceeds in the tens of millions of RMB. The Series A was led by Rainforest Fund under Zhongguancun Development Group, with existing shareholder FreeS Fund participating. The A+ was invested exclusively by Hejia Capital.

/ From the Investors /

UJet Future leverages interdisciplinary innovation capabilities, deeply integrating AI generative design algorithms with simulation physics models to solve deterministic design challenges in complex industrial scenarios. FreeS Fund has invested in UJet Future for three consecutive rounds since 2021.

We have witnessed UJet Future's OptFuture software grow from scratch to completing over 100 benchmark cases. This marks the transition of generative technology from "proof of concept" to "scaled deployment," while also demonstrating the innovation potential of domestic industrial software. We look forward to UJet Future continuing to drive the intelligent design ecosystem and helping China's high-end manufacturing move up the value chain.

/ About the Company /

UJet Future positions itself as "the next-generation generative design industrial software." It is a high-tech company independently developing a new-generation intelligent design topology optimization SaaS platform. In its four years since founding, the company achieved nearly 30 million RMB in business contracts in 2024. Its clients span leading enterprises including China North Industries Group, China Aerospace Science and Industry Corporation, Jiuzhou Yunjian, Meituan Drones, and Volkswagen, with initial commercial traction showing results.

This startup's products are gradually replacing overseas industrial design giants that previously held dominant positions in China, sparking an efficiency revolution in military, aerospace, and new energy vehicle sectors. (Coverage: Cyzone — Post-90s Top Student from Henan Builds "Industrial DeepSeek," Achieves Annual Revenue in the Millions, Military and Aerospace Firms Eager to Adopt)

▲ Image source: Chuguang 3D

FreeS Fund angel-round portfolio company Chuguang 3D announced the completion of a tens-of-millions RMB angel+ funding round. This round was led by Oriza Seed Capital, with Optics Valley Industry Investment and Changshu Guofa Venture Capital co-investing, and existing shareholder FreeS Fund reinvesting.

/ From the Investors /

As advanced manufacturing capabilities and their applications drive rapid development across related industries, demand for high-precision imaging — particularly micro- and nano-scale 3D imaging — will grow quickly.

The Chuguang team, drawing on years of industry experience and research accumulation, and building on technical foundations in spectral confocal and coded imaging, can rapidly provide solutions for high-speed, high-precision measurement of micro- and nano-scale 3D structures. We look forward to Chuguang becoming a leading precision metrology platform company amid the wave of industrial upgrading and advanced manufacturing.

/ About the Company /

Precision optical inspection instrument manufacturer Chuguang 3D was founded in 2022, specializing in research on new optical 3D imaging and metrology inspection technologies at micro- and nano-scale precision. The company is committed to building a next-generation 3D imaging technology platform and becoming a global leading provider of optical micro- and nano-scale 3D perception and metrology inspection solutions.

Chuguang 3D has released revolutionary 3D microscopic imaging products — the surface confocal 3D microscopic sensor and surface confocal 3D microscope/profilometer. These products employ an entirely new technical approach based on wide-field microscopic imaging principles, using structured light illumination to modulate surface information of measured objects, eliminating out-of-focus signal interference, and obtaining micro-surface 3D morphology through vertical axial scanning. Applicable to both complex-featured surfaces (such as scattering surfaces) and smooth surfaces, with flexible Z-axis precision adjustment from 1 nm to 1 μm depending on application scenarios. (Coverage: Yingke — HUST-Backed Wuhan High-End Equipment Company Secures Tens-of-Millions in Funding)

▲ VC Perspectives on the Two Sessions: Six Core Topics and Related Policy Analysis | FreeS Research ▲ Year-End Approaches: 5 Companies Move Into 2025 With New Funding | FreeS Family Funding News Vol. 21 ▲ Embodied Intelligence, AI+Industry, Chips+Intelligent Driving: 5 Companies Announce Funding | FreeS Family Funding News Vol. 20 ▲ New Listings and New Funding: 10 Summer Updates | FreeS Family Funding News Vol. 19 ▲ 4 Funding Announcements Arriving With Spring | FreeS Family Funding News Vol. 18

Star the FreeS Fund WeChat Official Account for timely business insights